Recom Managed Systems to Begin Trading on the American Stock Exchange.

LOS ANGELES -- first graph, last sentence should read: Recom anticipates trading of its Common Stock to commence on Wednesday, June 8, at 9:30 AM EDT under the ticker symbol RSY (sted Wednesday, June 15).

The corrected release reads:

RECOM MANAGED SYSTEMS TO BEGIN TRADING ON THE AMERICAN STOCK EXCHANGE 

Recom Managed Systems (OTCBB: RECM) has been notified by the American Stock Exchange that it has been approved for the listing of its Common Stock. This approval is contingent upon the Company's being in compliance with all applicable listing standards on the date it begins trading on the Exchange and may be rescinded if the Company is not in compliance with such standards. Recom anticipates trading of its Common Stock to commence on Wednesday, June 8, at 9:30 AM EDT under the ticker symbol RSY.

Recom will create new stock certificates to conform to the American Stock Exchange security requirements. Current Recom shareholders are not required to exchange their old stock certificates until a transaction requiring a new certificate occurs. However, to ensure a smooth transition from the OTC Bulletin Board to the American Stock Exchange, the Company suggests that shareholders send written instruction by fax or postal mail to their brokers and order new certificates for the shares they have on deposit and then deposit these new certificates into their accounts.

"The listing of Recom's shares on the American Stock Exchange is a landmark achievement for the Company and the culmination of all the hard work the management team has done over the past several months in advance of the commercialization of our revolutionary heart-monitoring technology," said Pamela Bunes, president and chief executive officer of Recom. "The new management at the Exchange has expressed a desire to cultivate listings of innovative small- and mid-cap companies, and we believe that AMEX provides an ideal fit for Recom."

Breakthrough ECG Monitoring Technology

Recom's first product, the Model 100 Heart Monitor, is an ambulatory patient heart monitor that uses patented signal-processing technology to record a clinical-quality ECG signal in the presence of "noise," or interference, generated by the patient's body movements and ambient environment. By reducing these interfering factors during recordings, the Recom Model 100 helps family practitioners, internists and cardiologists more accurately detect cardiac abnormalities or changes that may occur during daily activities and allows medical experts to collect extensive, continuous cardiac data over time, which can establish a baseline against which future readings can be compared. The Model 100 provides up to 48 hours of real-time heart monitoring during patients' everyday activities. The Model 100 has received 510(k) clearance from the Food and Drug Administration (FDA).

About Recom Managed Systems, Inc.

Recom Managed Systems, Inc. is an emerging life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Recom Managed Systems, Inc. uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. With our patented signal-technology platform, Recom brings clinical-quality physiological signal monitoring to the ambulatory setting.

Recom Managed Systems, Inc. is currently traded on the OTC Bulletin Board under the symbol RECM.OB. More information is located at http://www.recom-systems.com.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknown risks, which may cause Recom's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of new products or services, failure to obtain federal or state regulatory approvals governing medical devices, monitoring and other related services or products, inability to obtain physician, patient or insurance acceptance of Recom's products or services, adverse equity-market conditions and declines in the value of Recom's common stock, and the unavailability of financing to complete management's plans and objectives. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Recom's filings with the Securities and Exchange Commission.